A woman's proliferative diabetic retinopathy resolved within 6 weeks of starting semaglutide, even without significant improvement in blood sugar control.
6 weeksTime for proliferative diabetic retinopathy to resolve after starting semaglutide, despite minimal glycaemic change
What the researchers found
A 47-year-old woman with type 2 diabetes and proliferative diabetic retinopathy (PDR) showed resolution of new blood vessel growth in her right eye and improved diabetic macular oedema within just 6 weeks of starting semaglutide therapy. Notably, this improvement occurred despite minimal changes in her blood sugar control, suggesting semaglutide may have a direct, independent effect on diabetic eye disease beyond its glucose-lowering properties.
Why it matters
Proliferative diabetic retinopathy is a sight-threatening complication of diabetes that typically requires laser treatment or eye injections. If semaglutide can independently reverse this condition — not just through better blood sugar control — it would represent an unexpected and significant additional benefit of GLP-1 therapy for the millions of diabetics at risk of vision loss.
The numbers in context
1 patient · 47 years old · Resolution within 6 weeks · Minimal glycaemic change
How the study worked
Single case report describing a 47-year-old woman with type 2 diabetes, obesity, hypertension, and dyslipidaemia who had PDR in her right eye and severe nonproliferative diabetic retinopathy in her left eye. After starting semaglutide (originally prescribed for diabetes/weight management), her retinopathy was reassessed clinically.
Who was studied
Single 47-year-old woman with type 2 diabetes, obesity, and proliferative diabetic retinopathy
What this study cannot tell us
This is a single case report — the lowest level of clinical evidence. It cannot establish causation, and the improvement could be coincidental or due to other factors not controlled for. Large controlled studies are needed to confirm any direct retinal effect of semaglutide.
How to read the evidence
This is a single case report, which provides the lowest level of clinical evidence. While intriguing, one patient's experience cannot establish causation or be generalized to other patients without controlled trials.
When this study was published
Published in 2024, this case report reflects the growing interest in semaglutide's effects beyond metabolic parameters and is relevant to ongoing research into GLP-1 drugs and diabetic complications.
The bigger picture
There has been concern that rapid blood sugar reduction with GLP-1 drugs could initially worsen diabetic retinopathy. This case report suggests the opposite may be possible — that semaglutide could have direct protective effects on the retina. If confirmed in larger studies, this would add eye protection to semaglutide's growing list of benefits beyond glucose control.
Questions still open
- Does semaglutide have a direct anti-angiogenic effect on retinal blood vessels independent of glucose control?
- Could GLP-1 receptor agonists reduce the need for laser treatment or anti-VEGF injections in diabetic eye disease?
- Is this finding reproducible in controlled clinical trials with larger patient populations?
Common questions
Can semaglutide treat diabetic eye disease?
What is proliferative diabetic retinopathy?
Read the original research
Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report.
Case reports in ophthalmological medicine, 2024, 5834769
Citation
Cool, Daniel; Coventon, James; Sharma, Abhishek. (2024). Semaglutide Inducing Resolution of Proliferative Diabetic Retinopathy: A Case Report.. Case reports in ophthalmological medicine, 2024, 5834769. https://doi.org/10.1155/crop/5834769